Get the Stockscreener App
5.88
0.51%
-0.03
After Hours:
5.98
0.10
+1.70%
Iovance Biotherapeutics Inc stock is traded at $5.88, with a volume of 11.42M.
It is down -0.51% in the last 24 hours and down -20.33% over the past month.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
See More
Previous Close:
$5.91
Open:
$5.99
24h Volume:
11.42M
Relative Volume:
1.58
Market Cap:
$1.79B
Revenue:
$32.77M
Net Income/Loss:
$-440.22M
P/E Ratio:
-3.521
EPS:
-1.67
Net Cash Flow:
$-400.48M
1W Performance:
-0.17%
1M Performance:
-20.33%
6M Performance:
-26.13%
1Y Performance:
-24.42%
1-Day Range:
$5.57
$6.06
1-Week Range:
$5.57
$6.28
52-Week Range:
$5.57
$18.33
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Name
Iovance Biotherapeutics Inc
Sector
Industry
Phone
(650) 260-7120
Address
825 INDUSTRIAL ROAD, SAN CARLOS
Compare IOVA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
5.88 | 1.79B | 32.77M | -440.22M | -400.48M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-24 | Initiated | UBS | Buy |
| Jul-29-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-20-23 | Initiated | Goldman | Buy |
| Sep-18-23 | Reiterated | Barclays | Overweight |
| May-30-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-27-23 | Resumed | Wells Fargo | Equal Weight |
| Jan-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-09-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-31-22 | Initiated | Guggenheim | Neutral |
| Aug-18-22 | Resumed | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Stifel | Hold → Buy |
| Dec-07-21 | Resumed | Cowen | Outperform |
| Jun-10-21 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| May-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-19-21 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| May-19-21 | Downgrade | Stifel | Buy → Hold |
| May-03-21 | Initiated | Truist | Buy |
| Apr-16-21 | Initiated | Goldman | Buy |
| Mar-08-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-15-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-06-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-22-20 | Initiated | Mizuho | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Reiterated | H.C. Wainwright | Buy |
| Feb-26-20 | Reiterated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | JMP Securities | Mkt Outperform |
| Oct-01-19 | Initiated | Stifel | Buy |
| Apr-29-19 | Initiated | Piper Jaffray | Overweight |
| Feb-28-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-07-19 | Initiated | Robert W. Baird | Outperform |
| Dec-31-18 | Resumed | B. Riley FBR | Buy |
| Jul-06-18 | Reiterated | Chardan Capital Markets | Buy |
| Apr-10-18 | Upgrade | B. Riley FBR, Inc. | Neutral → Buy |
| Mar-13-18 | Reiterated | B. Riley FBR, Inc. | Neutral |
| Feb-23-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Jan-25-18 | Reiterated | H.C. Wainwright | Buy |
| Nov-01-17 | Reiterated | B. Riley FBR, Inc. | Buy |
View All
Iovance Biotherapeutics Inc Stock (IOVA) Latest News
(IOVA) Technical Pivots with Risk Controls - Stock Traders Daily
Iovance Biotherapeutics (NASDAQ:IOVA) Sets New 52-Week LowHere's Why - MarketBeat
Cervical Cancer Market Expected to Experience Major Growth - openPR
Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks - Insider Monkey
Is Iovance Biotherapeutics (IOVA) Among Billionaire Joseph Edelman’s Long-Term Stock Picks? - Yahoo Finance
1,746,877 Shares in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Purchased by Assenagon Asset Management S.A. - MarketBeat
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Iovance Biotherapeutics Awards 224,550 Stock Options to Expand Team with 41 New Hires - StockTitan
First Week of September 19th Options Trading For Iovance Biotherapeutics (IOVA) - Nasdaq
Iovance Biotherapeutics (NASDAQ:IOVA) Sets New 1-Year LowTime to Sell? - MarketBeat
Oversold Conditions For Iovance Biotherapeutics (IOVA) - Nasdaq
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) May Have Run Too Fast Too Soon With Recent 25% Price Plummet - Simply Wall St
How To Trade (IOVA) - Stock Traders Daily
Cancer Drug Maker Iovance Tumbles Toward Worst Week Since November, But Retail Feels Macro Selloff Overblown - MSN
Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 7.8%Here's Why - MarketBeat
Iovance Biotherapeutics Shares Are Falling Today: What's Going On? - Benzinga
Immunotoxins Market Trends and Regional Business Opportunities, 2024-2034: Diphtheria Toxin-Based Immunotoxins Lead Revenue, Pseudomonas Exotoxins Show Rapid Growth Potential - GlobeNewswire Inc.
Iovance Biotherapeutics (IOVA) Surges on Positive Analyst Outloo - GuruFocus.com
Why Iovance Biotherapeutics Stock Zoomed More Than 5% Higher Today - MSN
Stifel maintains Buy on Iovance Biotherapeutics stock, optimistic on Amtagvi By Investing.com - Investing.com Canada
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 7.7%What's Next? - MarketBeat
Why Iovance Biotherapeutics Inc. (IOVA) Is Skyrocketing - MSN
Analysts Set Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Price Target at $23.00 - MarketBeat
Philly’s year in biopharma: a look back at 2024 - The Philadelphia Inquirer
The Immunotherapy Boom: What It Means for the Future of Cancer Treatment - Baystreet.ca
Principal Financial Group Inc. Has $37.87 Million Stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat
Geode Capital Management LLC Cuts Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Purchased by Barclays PLC - MarketBeat
Where are the Opportunities in (IOVA) - Stock Traders Daily
Insiders' US$48.3m Investments In Red Following Iovance Biotherapeutics' US$402m Dip In Market Value - Simply Wall St
Iovance Biotherapeutics is Now Oversold (IOVA) - Nasdaq
KEI Comments on NIH Exclusive License to Iovance for T-cell Vaccine for Cancer Treatment - Knowledge Ecology International
Iovance Biotherapeutics: Amtagvi Launch Growing, But Stock Isn't (NASDAQ:IOVA) - Seeking Alpha
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Sees Significant Increase in Short Interest - MarketBeat
State Street Corp Grows Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat
Iovance Biotherapeutics' SWOT analysis: promising TIL therapy stock faces growth hurdles - Investing.com India
Interesting IOVA Call Options For January 2025 - Nasdaq
Prediction: This Stock Will Beat the Market in 2025 - Yahoo Finance
BNP Paribas Financial Markets Trims Stock Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat
Iovance Biotherapeutics' SWOT analysis: stock shows promise amid challenges By Investing.com - Investing.com Nigeria
Iovance Biotherapeutics: Steady Progress (NASDAQ:IOVA) - Seeking Alpha
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Iovance Biotherapeutics Inc Stock (IOVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):